ReviewFrontiers in immunology2022

Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications.

Carlos Wagner S Wanderley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.